Tao Ning
Overview
Explore the profile of Tao Ning including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
155
Citations
3467
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu R, Ji Z, Wang X, Zhu L, Xin J, Ma L, et al.
Nat Commun
. 2025 Feb;
16(1):1481.
PMID: 39929851
Immune checkpoint inhibitors (ICIs) have limited efficacy in microsatellite stable (MSS) metastatic colorectal cancer (mCRC), and combination therapy needs to be further explored. In this single-arm, open-label, phase II trial...
2.
Guo H, Xue Z, Mei S, Li T, Yu H, Ning T, et al.
Front Cell Infect Microbiol
. 2025 Jan;
14():1521199.
PMID: 39831106
Objective: The purpose of this study was to investigate the clinical efficacy of antibiotic-loaded bone cement (ALBC) combined with Negative pressure wound therapy (NPWT) aspiration technique in the treatment of...
3.
Liu R, Ji Z, Wang X, Xin J, Zhu L, Ge S, et al.
Invest New Drugs
. 2025 Jan;
43(1):81-92.
PMID: 39760815
Pancreatic cancer patients urgently need new treatments, and we explored the efficacy and safety of combination therapy with AL2846 and gemcitabine in pancreatic cancer patients. This was a single-arm, single-center,...
4.
Shen N, Wu R, Lu T, Jiang Y, Ning T, Liu S, et al.
BMC Infect Dis
. 2024 Nov;
24(1):1331.
PMID: 39574007
Background: The association between alterations in the oral microbiome and hand, foot, and mouth disease (HFMD) has been observed in previous studies. Our study, therefore, aimed to identify the structural...
5.
Yang H, Zhang H, Yang Y, Wang X, Deng T, Liu R, et al.
Theranostics
. 2024 Jun;
14(8):3081.
PMID: 38855172
[This corrects the article DOI: 10.7150/thno.44419.].
6.
Deng T, Wang F, Zhang L, Ning T, Sun Y, Ge S, et al.
Cancer Immunol Immunother
. 2024 Jun;
73(8):154.
PMID: 38833154
Background: Alpha-fetoprotein elevated gastric cancer (AFPGC) got growing interests for its aggressive nature and unfavorable prognosis. Here, a phase 1 dose escalation study was conducted to evaluate safety and efficacy...
7.
Ning T, Li D, Deng T, Bai Y, Chen Y, Wang Z, et al.
Cancer
. 2024 May;
130(18):3137-3146.
PMID: 38781433
Background: Effective systemic therapy remains limited for advanced esophageal squamous cell carcinoma (ESCC) and hepatocellular carcinoma (HCC), particularly after prior failed treatment with immune checkpoint inhibitors (ICIs). Theoretically, a combination...
8.
Li T, Ning T, Liu X, Zhao C, Shi X, Xu G
J Chromatogr A
. 2024 May;
1727:464970.
PMID: 38744187
The extensive usage of neonicotinoid insecticides (NIs) has raised many concerns about their potential harm to environment and human health. Thus, it is of great importance to develop an efficient...
9.
Duan J, Zhu L, Shi Y, Wang W, Wang T, Ning T, et al.
BMC Cancer
. 2024 Mar;
24(1):302.
PMID: 38443891
Background: There are various recommendations for third-line treatment in mCRC, however, there is no consensus on who is more suitable for particular strategy. Chemotherapy re-use in third-line setting is a...
10.
Yang Y, Tan H, Lu Y, Mei J, Zhang M, Bai M, et al.
BMC Cancer
. 2024 Feb;
24(1):249.
PMID: 38389042
Background: Increasing evidence has showed that inflammatory biomarkers, including neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and fibrinogen can be used as predictors in the prognosis of...